Histone deacetylase inhibitor romidepsin inhibits De Novo HIV-1 infections

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3984-3994

  Jønsson, Kasper L ^a,b   Tolstrup, Martin ^c,d   Vad Nielsen, Johan ^c   Kjær, Kathrine ^a   Laustsen, Anders ^a,b   Andersen, Morten N ^a   Rasmussen, Thomas A ^c   Søgaard, Ole S ^c,d   Østergaard, Lars ^c,d   Denton, Paul W ^c,d   Jakobsen, Martin R ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b Aarhus Research Center for Innate Immunology   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PANOBINOSTAT; ROMIDEPSIN; ANTIVIRUS AGENT; DEPSIPEPTIDE; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR;

ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIROGENESIS; VIRUS ACTIVATION; VIRUS LATENCY; WILD TYPE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; HIV INFECTIONS; MONOCYTE; PRIMARY CELL CULTURE; VIROLOGY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; DEPSIPEPTIDES; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; MONOCYTES; PRIMARY CELL CULTURE; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84935868889     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00574-15     Document Type: Article

References (55)

1. Eisele E, Siliciano RF. 2012. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37:377-388. http://dx.doi.org/10.1016/j.immuni.2012.08.010.
2. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. 2009. The challenge of finding a cure for HIV infection. Science 323:1304-1307. http://dx.doi.org/10.1126/science.1165706.
3. Deeks SG. 2012. HIV: shock and kill. Nature 487:439-440. http://dx.doi.org/10.1038/487439a.
4. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Mascio MD, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, Telenti A, Lint CV, Verdin E, Woolfrey A, Zaia J, Barre-Sinoussi F. 2012. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12:607-614. http://dx.doi.org/10.1038/nri3262.
5. Durand CM, Blankson JN, Siliciano RF. 2012. Developing strategies for HIV-1 eradication. Trends Immunol 33:554-562. http://dx.doi.org/10.1016/j.it.2012.07.001.
6. Dahl V, Josefsson L, Palmer S. 2010. HIV reservoirs, latency, and reactivation: prospects for eradication. Antivir Res 85:286-294. http://dx.doi.org/10.1016/j.antiviral.2009.09.016.
7. Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. 2014. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol 12:750-764. http://dx.doi.org/10.1038/nrmicro3352.
8. Colin L, Van Lint C. 2009. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111. http://dx.doi.org/10.1186/1742-4690-6-111.
9. Rasmussen TA, Schmeltz-Sogaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, Dinarello C, Ostergaard L, Tolstrup M. 2013. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccines Immunother 9:993-1001. http://dx.doi.org/10.4161/hv.23800.
10. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM. 2009. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 83:4749-4756. http://dx.doi.org/10.1128/JVI.02585-08.
11. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. 2009. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 23:1799-1806. http://dx.doi.org/10.1097/QAD.0b013e32832ec1dc.
12. Wightman F, Lu HK, Solomon AE, Saleh S, Harman AN, Cunningham AL, Gray L, Churchill M, Cameron PU, Dear AE, Lewin SR. 2013. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 27:2853-2862. http://dx.doi.org/10.1097/QAD.0000000000000067.
13. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. 2011. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 286:22211-22218. http://dx.doi.org/10.1074/jbc.M110.180224.
14. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T. 2014. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10:e1004071. http://dx.doi.org/10.1371/journal.ppat.1004071.
15. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS. 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-e21. http://dx.doi.org/10.1016/S2352-3018(14)70014-1.
16. th International AIDS Conference (AIDS 2014), Melbourne, Australia.
17. + T cells to HIV by increasing the kinetics and efficiency of postentry viral events. J Virol 88:10803-10812. http://dx.doi.org/10.1128/JVI.00320-14.
18. Campbell GR, Bruckman RS, Chu YL, Spector SA. 2015. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. J Biol Chem 290:5028-5040. http://dx.doi.org/10.1074/jbc.M114.605428.
19. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111:2307-2312. http://dx.doi.org/10.1073/pnas.1318249111.
20. Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, Siliciano JD, Siliciano RF. 2013. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 9:e1003398. http://dx.doi.org/10.1371/journal.ppat.1003398.
21. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 83:8289-8292. http://dx.doi.org/10.1128/JVI.00709-09.
22. Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gamma-retroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 82:12585-12588. http://dx.doi.org/10.1128/JVI.01726-08.
23. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905. http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002.
24. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74:8358-8367. http://dx.doi.org/10.1128/JVI.74.18.8358-8367.2000.
25. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72:2855-2864.
26. National Center for Biotechnology Information. 2015, posting date. PubChem Compound Database: CID 6918837. Panobinostat compound summary. National Center for Biotechnology Information, Bethesda, MD.
27. National Center for Biotechnology Information. 2015. PubChem Compound Database: CID 5352062. Romidepsin compound summary. National Center for Biotechnology Information, Bethesda, MD.
28. Atadja P. 2009. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280:233-241. http://dx.doi.org/10.1016/j.canlet.2009.02.019.
29. Rasmussen TA, Tolstrup M, Winckelmann A, Ostergaard L, Sogaard OS. 2013. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccines Immunother 9:790-799. http://dx.doi.org/10.4161/hv.23202.
30. Ratner L, Fisher A, Jagodzinski LL, Mitsuya H, Liou RS, Gallo RC, Wong-Staal F. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses 3:57-69. http://dx.doi.org/10.1089/aid.1987.3.57.
31. + T cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 304:3-15.
32. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 86:2365-2368. http://dx.doi.org/10.1073/pnas.86.7.2365.
33. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W, Barstad P, Kovacs J, Fauci AS, Folks TM. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 142:431-438.
34. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20:425-429. http://dx.doi.org/10.1038/nm.3489.
35. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188. http://dx.doi.org/10.1038/387183a0.
36. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300. http://dx.doi.org/10.1126/science.278.5341.1295.
37. + T cells. AIDS 22:1131-1135. http://dx.doi.org/10.1097/QAD.0b013e3282fd6df4.
38. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555. http://dx.doi.org/10.1016/S0140-6736(05)67098-5.
39. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
40. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, Lichterfeld M, Kovacs C, Ostrowski MA, Trocha A, Irvine DJ, Walker BD. 2014. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T lymphocytes. PLoS Pathog 10:e1004287. http://dx.doi.org/10.1371/journal.ppat.1004287.
41. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sekaly RP, Lewin SR. 2014. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 10: e1004473. http://dx.doi.org/10.1371/journal.ppat.1004473.
42. Remoli AL, Marsili G, Battistini A, Sgarbanti M. 2012. The development of immune-modulating compounds to disrupt HIV latency. Cytokine Growth Factor Rev 23:159-172. http://dx.doi.org/10.1016/j.cytogfr.2012.05.003.
43. Rigby L, Muscat A, Ashley D, Algar E. 2012. Methods for the analysis of histone H3 and H4 acetylation in blood. Epigenetics 7:875-882. http://dx.doi.org/10.4161/epi.20983.
44. Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D, Altucci L, Palamara AT, Garaci E. 2009. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6:52. http://dx.doi.org/10.1186/1742-4690-6-52.
45. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212. http://dx.doi.org/10.1089/aid.2008.0191.
46. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. http://dx.doi.org/10.1038/nature11286.
47. + T cells. J Infect Dis 197:1162-1170. http://dx.doi.org/10.1086/529525.
48. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. 2004. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18:1101-1108. http://dx.doi.org/10 .1097/00002030-200405210-00003.
49. Jang JS, Simon VA, Feddersen RM, Rakhshan F, Schultz DA, Zschunke MA, Lingle WL, Kolbert CP, Jen J. 2011. Quantitative miRNA expression analysis using Fluidigm microfluidics dynamic arrays. BMC Genomics 12:144. http://dx.doi.org/10.1186/1471-2164-12-144.
50. Sarkar SN, Sen GC. 2004. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacol Ther 103:245-259.
51. Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue AJ, Todorovic A, Morris JH, Maltby DA, Alber T, Cagney G, Bushman FD, Young JA, Chanda SK, Sundquist WI, Kortemme T, Hernandez RD, Craik CS, Burlin-game A, Sali A, Frankel AD, Krogan NJ. 2012. Global landscape of HIV-human protein complexes. Nature 481:365-370. http://dx.doi.org/10.1038/nature10719.
52. Valente ST, Gilmartin GM, Mott C, Falkard B, Goff SP. 2009. Inhibition of HIV-1 replication by eIF3f. Proc Natl Acad Sci U S A 106:4071-4078. http://dx.doi.org/10.1073/pnas.0900557106.
53. Okumura A, Lu G, Pitha-Rowe I, Pitha PM. 2006. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci U S A 103:1440-1445. http://dx.doi.org/10.1073/pnas.0510518103.
54. Morales DJ, Lenschow DJ. 2013. The antiviral activities of ISG15. J Mol Biol 425:4995-5008. http://dx.doi.org/10.1016/j.jmb.2013.09.041.
55. Decker T. 1999. Introduction: STATs as essential intracellular mediators of cytokine responses. Cell Mol Life Sci 55:1505-1508. http://dx.doi.org/10.1007/s000180050390.